咨询与建议

看过本文的还看了

相关文献

该作者的其他文献

文献详情 >Case of Advanced Recurrent Gli... 收藏

Case of Advanced Recurrent Glioblastoma Successfully Treated with Monoterpene Perillyl Alcohol by Intranasal Administration

Case of Advanced Recurrent Glioblastoma Successfully Treated with Monoterpene Perillyl Alcohol by Intranasal Administration

作     者:C. O. Da Fonseca Raphael M. Teixeira Ricardo Ramina Giovana Kovaleski Júlio Thome Silva Janaína Nagel Thereza Quirico-Santos 

作者机构:Department of General and Specialized Surgery Unit of Clinical Research Fluminense Federal University Institute of Biology Fluminense Federal University Institute of Neurology of Curitiba 

出 版 物:《Journal of Cancer Therapy》 (癌症治疗(英文))

年 卷 期:2011年第2卷第1期

页      面:16-21页

学科分类:1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

主  题:Glioblastoma Long-term Survival Perillyl Alcohol Intranasal Administration 

摘      要:We report a case of recurrent glioblastoma (GBM) successfully treated with the Ras inhibitor monoterpene perillyl alcohol by intranasal administration. A 37-years-old white woman had been previously submitted to three neurosurgical procedures, in June 2000 for radical tumor excision of grade II astrocytoma;in July 2003 for first recurrence of type IV glioma and in August 2004 for GBM recurrence. After last surgery, patient started a new cycle of chemotherapy but was refractory to treatment, presented clinical adverse effects and resonance image scan showed no reduction of tumoral lesion. Patient was then considered out of therapeutic possibilities and indicated for supportive treatment. On March 2005 patient joined Phase I/II clinical trial for assess the efficacy of the monoterpene POH, a Ras inhibitor. POH was administered by intranasal route four times a day (268 mg daily) as single chemotherapy agent. Image scans performed 3 and 5 years later revealed marked reduction of enhancing lesion. This illustrative case demonstrates that intranasal administration of the monoterpene POH as a single agent was an effective therapeutic strategy capable to sustain long-term regression of recurrent glioma without clinical and laboratory toxicity.

读者评论 与其他读者分享你的观点

用户名:未登录
我的评分